Office of the President continues to perform the duties of President and CEO
REDWOOD CITY, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Chairman, President and Chief Executive Officer Paul J. Hastings will resume his Chairman of the Board responsibilities, effective December 4, 2017.
The Office of the President, comprised of Executive Vice President, Research and Development, John Lewicki, and Executive Vice President and Chief Financial Officer, Sunil Patel, will continue to perform the duties of President and CEO. The Office of the President will continue to report to a special committee of the Board of Directors composed of Deepa Pakianathan, Jack Lasersohn, Rick Winningham and Perry Karsen.
Read More: http://www.oncomed.com/invest/releasedetail.cfm?ReleaseID=1049868